These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38561511)

  • 61. Detection and analysis of signals of adverse events of memantine based on the US food and drug administration adverse event reporting system.
    Zhang W; Chen M; Cai X; Zhang M; Hu M; Hu Y; Yang Y; Zhu J; Du Y; Yang C
    Expert Opin Drug Saf; 2024 May; 23(5):617-625. PubMed ID: 38568141
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system.
    Shu Y; Ding Y; Dai B; Zhang Q
    Expert Opin Drug Saf; 2022 Apr; 21(4):563-572. PubMed ID: 34918584
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database.
    Liu L
    Front Pharmacol; 2024; 15():1397029. PubMed ID: 38910884
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Data mining and analysis for emicizumab adverse event signals based on the Food and Drug Administration Adverse Event Reporting System database.
    Wei L; Tian Y; Chen X; Guo X; Chen C; Zheng Y; Xu J; Ye X
    Int J Clin Pharm; 2023 Jun; 45(3):622-629. PubMed ID: 36848023
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010-2019.
    Setyawan J; Azimi N; Strand V; Yarur A; Fridman M
    Drug Saf; 2021 Aug; 44(8):889-897. PubMed ID: 34120321
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Unveiling the adverse events of Nusinersen in spinal muscular atrophy management based on FAERS database.
    Jiang Y; Shen Y; Zhou Q; Zhu H
    Sci Rep; 2024 Jul; 14(1):17138. PubMed ID: 39060346
    [TBL] [Abstract][Full Text] [Related]  

  • 68. A real-world pharmacovigilance study of abaloparatide based on the FDA Adverse Event Reporting System (FAERS).
    Shi X; Cheng Q; Zhao YZ; Zou SP; Sun MH
    Osteoporos Int; 2023 Dec; 34(12):2047-2058. PubMed ID: 37594595
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
    Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
    ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
    Welch HK; Kellum JA; Kane-Gill SL
    Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Clinical adverse events to dexmedetomidine: a real-world drug safety study based on the FAERS database.
    Liu F; Zheng JX; Wu XD
    Front Pharmacol; 2024; 15():1365706. PubMed ID: 39015372
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Analysis of eplerenone in the FDA adverse event reporting system (FAERS) database: a focus on overall patient population and gender-specific subgroups.
    Guan X; Yang Y; Li X; Feng Y; Li J; Li X
    Front Pharmacol; 2024; 15():1417951. PubMed ID: 39086389
    [No Abstract]   [Full Text] [Related]  

  • 73. Analysis of Inclisiran in the US FDA Adverse Event Reporting System (FAERS): a focus on overall patient population and sex-specific subgroups.
    He Y; Guan X; Zhang Y; Zhu Z; Zhang Y; Feng Y; Li X
    Expert Opin Drug Saf; 2024 May; ():1-9. PubMed ID: 38676389
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system.
    Xiong R; Lei J; Pan S; Zhang H; Tong Y; Wu W; Huang Y; Lai X
    Front Pharmacol; 2023; 14():1226086. PubMed ID: 37781705
    [No Abstract]   [Full Text] [Related]  

  • 75. Novel insights into post-marketing AEs associated with leuprorelin: A comprehensive analysis utilizing the FAERS database.
    Han H; Bu X; Wang X; Chen S; Tian N; Jin J; Feng Q; Ma B; Teng J; Li Z
    Heliyon; 2024 Aug; 10(15):e34969. PubMed ID: 39157412
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Assessing the safety of bedaquiline: insight from adverse event reporting system analysis.
    Wu J; Pan H; Shen L; Zhao M
    Front Pharmacol; 2024; 15():1382441. PubMed ID: 38783951
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A real-world data analysis of acetylsalicylic acid in FDA Adverse Event Reporting System (FAERS) database.
    Zhao B; Zhang X; Chen M; Wang Y
    Expert Opin Drug Metab Toxicol; 2023; 19(6):381-387. PubMed ID: 37421631
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Novel insights into post-marketing adverse events associated with lenvatinib: A comprehensive analysis utilizing the FAERS database.
    Yu Z; Luo J; Wei H
    Heliyon; 2024 Mar; 10(6):e28132. PubMed ID: 38524578
    [TBL] [Abstract][Full Text] [Related]  

  • 80. A real-world pharmacovigilance study of FDA adverse event reporting system events for atogepant.
    Wen H; Ding Y; Chen F
    Expert Opin Drug Saf; 2024 Jul; ():1-8. PubMed ID: 38970172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.